Coulter Partners: Top global hires Large-cap, mid-cap and public companies

Announcement of a placement, working with an international biotech backed by UK and global VCs.

This strategic hire marks a significant step in the firm’s expansion within the Swiss market and the broader DACH region.

As custodians of the triple award-winning Advanced Therapies Apprenticeship Community (ATAC), Cell and Gene Therapy Catapult are excited to announce that we are sponsoring the first ever Apprentice of the Year award at the ever-popular annual bioProcessUK Conference, taking place in Newcastle on 25-27 November 2025.

Myricx Bio (‘Myricx’), a private biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is scaling ahead of entering the clinic and is pleased to announce the appointment of Boston-based Mohit Rawat as its Chief Executive Officer (CEO) and member of the Board of Directors.

Coulter Partners successfully completed a search assignment for Alltrna and is pleased to announce the placement of Dave Hava, Ph.D. as Chief Scientific Officer (CEO).

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the appointment of four world leading experts to its Scientific Advisory Board (SAB).